During the past decade, nosocomial infections caused by methicillin-resistant
Staphylococcus aureus (MRSA) in hospitals have become a serious clinical problem1).
The glycopeptide antibiotic, vancomycin, has been used for the treatment of infections due to MRSA. Recently,
MRSA strains with intermediate resistance to vancoisolates2).
Therefore, a new anti-MRSA antibiotic, which differs from vancomycin in mode of action, is clinically of interest.
In the course of our screening system for new anti-MRSA antibiotics, a strain No. WAP-8294 belonging to the genus Lysobacter was found to produce a new peptide antibiotic which showed inhibitory activity against MRSA. It was isolated as a complex of WAP-8294A from the fermentation broth by chromatography. In the HPLC analysis of WAP-8294A complex, a major component WAP-8294A2 and 18 minor components were observed (Fig. 1) . Of those components, A1, A4, A2, Ax8, Ax9 and Ax13 were isolated (Fig. 2) . The structure of WAP-8294A2 had been reported in the previous communication3). The structure elucidation of the isolated components will be reported in detail in the subsequent paper4). The present paper deals with the taxonomy of the producing organism, fermentation, for 1 day on a rotary shaker (180rpm). A 2ml portion of the seed culture was transferred into a 500ml Erlenmeyer flask containing 100ml of the same medium.
shaker (180rpm). The antibiotic production in the fermentation broth was monitored by HPLC analysis and paper disc assay.
An example of the typical isolation is illustrated in Fig. 4 . The fermentation broth (5 liters) was mixed with equal volumes of ethanol (5 liters), and the mixture was adjusted to pH 2.5 with 6 N HCl. The mixture was centrifuged and the cell mass was discarded. The supernatant was passed through a column of Diaion HP-20 (Mitsubishi Chemical, Tokyo, Japan). The column was washed with water, 80% acetone (pH 11.0) and 80% acetone, and then eluted with 80% acetone containing 0.05% trifluoroacetic acid (TFA). The eluate was concentrated and freeze-dried to give the WAP-8294A complex (3.4g). 1998 results are shown in Table 2 . The properties of the main component WAP-8294A2 have been described in a previous communication3).
Antimicrobial Activity
The antimicrobial spectra of WAP-8294A1, A2, A4, Ax8, Ax9 and Ax13 are shown in Table 3 . The antibiotics were active against Gram-positive bacteria, including MRSA but inactive against Gram-negative bacteria, some fungi and yeasts. The activity of these antibiotics was highly enhanced by the addition of 10% human serum (about 2-to 8-fold). Moreover, WAP-8294A2 was active against vancomycin-resistant Enterococci (VRE) Cytotoxicity WAP-8294A2 showed a weak cytotoxic effect against Acute Toxicity
The acute toxicity of WAP-8294A2 was tested by oral (po), intravenous(iv) and intraperitoneal(ip) administration to mice. It was not toxic at 200mg/kg(po), 50mg/kg (iv) and 100mg/kg(ip).
Mode of Action
The bactericidal action of WAP-8294A2 was compared with vancomycin. As shown in Fig. 5 , WAP-8294A2 showed a clear bactericidal activity within 2 hours. On the contrary, vancomycin showed only a little bactericidal activity even after 6 hours. In addition, the activity of WAP-8294A2 was not inhibited by diacetyl-L-lysyl-D-alanyl-D-alanine which was a vancomycin antagonist, suggesting that the mode of action of WAP-8294A2 is different from that of vancomycin8). In the disc diffusion test, the anti-MRSA activity of WAP-8294A2 was inhibited by the addition of phosphatidylglycerol or cardiolipin to the disc (Table 4) . These results suggest that WAP-8294A2 interacts selectively with phospholipids in the target cell membrane resulting in its membrane damage. 
